The path to widespread clinical adoption of pharmacogenomic practices is currently being forged, not without difficulty, but also not without promise. "...most of us would agree that if we have information (genetic or otherwise) that can help select a drug type or dose or reduce adverse events or costs, we should consider this information in our decision-making," (Teng). Beyond the needed consideration of pharmacogenomic information in practice is the need for tools and direction to make it a reality. Read more from Dr. Kathryn Teng on the barriers to adoption and ways to circumvent the challenges that are currently being posed.